T cell balancing act

The latest debate in CAR T is whether CD8+ or CD4+ cells play the bigger role

Among the improvements to next-generation CAR T cell therapies is the need to optimize the ratios of the different T cell subsets. While CD8+ T cells have grabbed most of the attention, a study from City of Hope suggests that for some cancers, companies should look to CD4+ cells instead.

The dominant hypothesis is that CD8+ T cells are the primary cytotoxic agents in CAR T therapies. CD4+ T cells have played a Cinderella role, perceived as helpers that boost the killing power of their CD8+ counterparts.

But a growing body of research suggests CD4+ cells can directly kill tumors as well, raising the question of what balance of the cell types will provide the best therapy.

Two studies came to opposite conclusions. While a University of Pennsylvania study in Nature Medicine found CD8+ T cells were more powerful, the City of Hope , published in JCI Insight, argued that CD4+ cells drive bigger, longer lasting responses. Both studies were published last month.

First-wave CAR T therapies Kymriah tisagenlecleucel from Novartis AG and Yescarta axicabtagene ciloleucel from Gilead Sciences Inc. contain undefined mixtures of T cell subtypes that vary from patient to patient. The composition reflects the ratios present in the patient’s leukapheresis

Read the full 2010 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers